Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over technology in ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

THURSDAY, May 8, 2025 (HealthDay News) — A new vaccine that combines flu and COVID ... Moderna said it now expects that approval of the shot may not come until 2026. “I agree in this case ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Researchers from vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against COVID-19 ... agree in this case with FDA that ...

Moderna said on Thursday it now does not expect regulatory approval for its combination flu/COVID-19 shot until 2026, after the FDA said it required late-stage data demonstrating the shot's ...

Moderna researchers reported that the combo shot produced a stronger immune response against COVID-19 and most flu ... “I agree in this case with FDA that efficacy data are important to see ...